3/17/2024

Cefdinir Oral Presentations

Products Affected - Description

- Cefdinir oral capsule, Ascend, 300 mg, bottle, 60 count, NDC 67877-0543-60
- Cefdinir oral suspension, Ascend, 125 mg/5 mL, 100 mL bottle, NDC 67877-0547-88
- Cefdinir oral suspension, Ascend, 125 mg/5 mL, 60 mL bottle, NDC 67877-0547-98
- Cefdinir oral suspension, Ascend, 250 mg/5 mL, 100 mL bottle, NDC 67877-0548-88
- Cefdinir oral suspension, Ascend, 250 mg/5 mL, 60 mL bottle, NDC 67877-0548-98
- Cefdinir oral capsule, Lupin, 300 mg, bottle, 60 count, NDC 68180-0711-60
- Cefdinir oral suspension, Lupin, 125 mg/5 mL, 100 mL bottle, NDC 68180-0722-05
- Cefdinir oral suspension, Lupin, 125 mg/5 mL, 60 mL bottle, NDC 68180-0722-04
- Cefdinir oral suspension, Teva, 250 mg/5 mL, 60 mL bottle, NDC 00093-4137-64

Reason for the Shortage

- Ascend had cefdinir oral presentations on shortage due to increased demand.
- Aurobindo refuses to provide availability information.
- Lupin did not provide a reason for the shortage.
- Rising is shipping to forecast.
- Teva did not provide a reason for the shortage.

Available Products

- Cefdinir oral suspension, Lupin, 250 mg/5 mL, 100 mL bottle, NDC 68180-0723-05
- Cefdinir oral suspension, Lupin, 250 mg/5 mL, 60 mL bottle, NDC 68180-0723-04
- Cefdinir oral capsule, Rising Pharmaceuticals, 300 mg, bottle, 60 count, NDC 57237-0099-60
- Cefdinir oral capsule, Teva, 300 mg, bottle, 60 count, NDC 00093-3160-06
- Cefdinir oral suspension, Teva, 125 mg/5 mL, 100 mL bottle, NDC 00093-4136-73
- Cefdinir oral suspension, Teva, 125 mg/5 mL, 60 mL bottle, NDC 00093-4136-64
- Cefdinir oral suspension, Teva, 250 mg/5 mL, 100 mL bottle, NDC 00093-4137-73

Estimated Resupply Dates

- Ascend is shipping cefdinir oral presentations and wholesalers are allocating product.
- Lupin has cefdinir 125 mg/5 mL in 60 mL and 100 mL bottles and 300 mg capsules in 60 count bottles on back order and the company cannot estimate a release date.
- Teva has cefdinir 250 mg/5 mL in 60 mL on back order and the company estimates a release date of early-April 2024.

Updated

Updated March 17, 2024 by Elyse MacDonald, PharmD, MS, BCPS. Created June 29, 2023 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.